Back to Archived News
Provectus Pharmaceuticals Receives US Patent Providing Further Protection for Novel Agent PH-12
Tuesday, June 10, 2008
- Radiosensitizer Agents Make Radiation Therapy More Effective
- Intellectual Property Portfolio Includes 20 US Patents
Knoxville, TN -- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has received its third US patent protecting novel therapeutic agents and methods from the United States Patent and Trademark Office (USPTO). The current patent covers radiosensitizer agents based on PH-12, the Company’s novel analog of PV-10 and PH-10, designed to enhance effectiveness of radiation therapy.
"Radiosensitizers are not themselves radioactive, but instead, function by interacting with applied ionizing radiation to improve the local cancer-killing potential of the applied radiation," noted Craig Dees, PhD, CEO of Provectus. "This may allow cancers to be treated more selectively and with lower radiation doses. PH-12 takes advantage of the cancer targeting properties of PV-10, but has greater ability to interact with therapeutic radiation, making it a more natural fit for this class of therapeutic agent. We are still formulating plans for clinical development, but PH-12 radiosensitizers could be a good candidate for therapy used in conjunction with radiation to treat difficult visceral cancers, including pancreatic, lung or prostate cancer."
Dees continued, "While we remain very focused on the therapeutic uses of PV-10 as a stand-alone product category, we cannot ignore the large potential value of radiosensitizer products for cancer markets worldwide. Like our recently announced PET technology, protection of our platform technology in all potential areas of medical use enhances value for our shareholders."
This patent increases Provectus' US patent portfolio to twenty issued and two pending patents.
Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the Company's website at www.pvct.com Porter, LeVay & Rose, Inc. via the information provided below.
The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
Back to Archived News